Dr. Karina Allen Ludwig
Chemist, Aphios Pharma
Dr. Karina Allen-Ludwig is a chemist/biochemist at Aphios Corporation with expertise in the development, synthesis and analysis of small molecules. Dr. Ludwig has extensive experience with NMR, HPLC, GC, FTIR, UV-Vis, SPR and LC-MS in the analysis of peptides, synthetic organic molecules and enzymes, as well as experience in the use of molecular dynamics simulation software to predict the behavior of small molecules in aqueous environments. Dr. Ludwig developed a synthetic fluorescent peptide for the detection of endotoxin that may be used in lieu of the current detection systems.
Dr. Ludwig is the lead scientist on a multidisciplinary team developing methods to manufacture cannabidiol (CBD) from Cannabis sativa following current Good Manufacturing Practices (cGMP) guidelines of the United States Food and Drug Administration (US FDA). This research is being conducted under the auspices of Phase I and II Fast Track grants from the National Institute of Drug Abuse (NIDA). Additionally, Dr. Ludwig is part of a team developing a nanoparticle formulation of a super-hydrophobic drug, Brefeldin-A (BFA), a fungal metabolite that has demonstrated to reversibly interfere with anterograde transport from the endoplasmic reticulum to the Golgi apparatus. Under a contract with Leidos Biomedical, Aphios is developing a nanoformulation of BFA for the National Cancer (NCI) Institute to improve its pharmacokinetics and allow clinical trials of this promising anticancer drug.
Dr. Ludwig also has extensive experience in the design, development and implementation of secure computing networks for C2 and B1 operating systems, expertise in hardware and software implementation and optimization. Additional skills include: Unix/Linux experience, shell scripts, device management and implementation, C and C++ programming experience.